Shuling Guo, PhDVice President, Antisense Drug Discovery at Ionis Pharmaceuticals, Inc.Speaker
Profile
Dr. Shuling Guo received her Ph.D. in Molecular Cancer Biology from Duke University and had her postdoctoral training at HHMI/UCLA. At Ionis, Dr. Guo oversees drug discovery efforts in hematological, metabolic, ocular, pulmonary and renal disease areas as well as research efforts in noncoding RNA field. She manages activities from target identification, target validation to the selection of human development candidate. In addition, she is involved in clinical development of antisense therapies. Dr. Guo led the research efforts for transthyretin (familial amyloid polyneuropathy, completed phase 3 clinical trial & under NDA), TMPRSS6 (beta-thalassemia and hereditary hemochromatosis, phase 1 clinical trial), and ENaC (cystic fibrosis, preclinical development).